Jazz Pharmaceuticals PLC (JAZZ)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 749,278 | 767,027 | 679,209 | 637,402 | 719,765 | 629,155 | 604,865 | 608,223 | 581,802 | 823,016 | 703,283 | 474,880 | 475,907 | 337,090 | 514,928 | 788,202 | 435,130 | 286,821 | 265,492 | 269,465 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 4,093,760 | 4,171,070 | 3,762,600 | 3,696,460 | 3,737,000 | 3,489,370 | 3,525,680 | 3,335,040 | 3,085,730 | 2,745,190 | 3,200,780 | 3,608,490 | 3,965,190 | 3,938,480 | 4,131,490 | 3,797,690 | 3,659,740 | 3,377,200 | 3,141,800 | 2,808,500 |
| Return on total capital | 18.30% | 18.39% | 18.05% | 17.24% | 19.26% | 18.03% | 17.16% | 18.24% | 18.85% | 29.98% | 21.97% | 13.16% | 12.00% | 8.56% | 12.46% | 20.75% | 11.89% | 8.49% | 8.45% | 9.59% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $749,278K ÷ ($—K + $4,093,760K)
= 18.30%
Jazz Pharmaceuticals PLC's return on total capital has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ratio started at 9.59% in March 2020, decreased to 8.45% by June 2020, and then slightly increased to 8.49% by September 2020. There was a notable improvement in December 2020, with a return on total capital of 11.89%.
The ratio experienced significant growth in the following quarters, reaching a peak of 29.98% in September 2022. This exceptionally high return was followed by fluctuations in the range of 17% to 21% until December 2024, indicating relative stability in generating returns in the subsequent periods.
Overall, Jazz Pharmaceuticals PLC's return on total capital trended positively over the period, with occasional fluctuations but displaying an increasing and generally healthy performance in utilizing its capital effectively to generate returns for its shareholders.
Peer comparison
Dec 31, 2024